Table 2 Stratification analysis of factors influencing outcomes
Factors | DE + rh-endostatin (n = 33) OR (%) | DE (n = 31) OR (%) | pvalue |
|---|---|---|---|
Age, years | |||
30-40 | 4 (100.0) | 1 (100.0) | 1.0 |
40-60 | 23 (92.0) | 19 (76.0) | 0.247 |
>60 | 3 (75.0) | 1 (20.0) | 0.206 |
Menopausal status | |||
Premenopausal | 14 (100.0) | 6 (46.2) | 0.002 |
Postmenopausal | 15 (83.3) | 11 (78.6) | 1.0 |
ER status | |||
Positive | 17 (89.5) | 11 (73.3) | 0.210 |
Negative | 11 (91.7) | 9 (64.3) | 0.590 |
PR status | |||
Positive | 14 (93.3) | 9 (64.3) | 0.080 |
Negative | 14 (87.5) | 11 (73.3) | 0.394 |
HER2 status | |||
Positive | 6 (100.0) | 6 (85.7) | 1.0 |
Negative | 22 (91.7) | 13 (65.0) | 0.160 |
ECOG performance status | |||
0 | 17 (94.4) | 14 (66.7) | 0.049 |
1 | 10 (83.3) | 5 (62.5) | 0.347 |
2 | 3 (100.0) | 2 (100.0) | 1.0 |
Histology | |||
Ductal | 26 (89.7) | 19 (70.4) | 0.096 |
Lobular and others | 4 (100.0) | 2 (50.0) | 0.206 |
No. of metastatic lymph nodes | |||
0 | 16 (100.0) | 10 (83.3) | 0.175 |
1-3 | 4 (66.7) | 4 (36.4) | 0.335 |
4-9 | 6 (85.7) | 4 (80.0) | 1.0 |
≥10 | 4 (100.0) | 3 (100.0) | 1.0 |
TNM stage | |||
II | 20 (90.9) | 13 (68.4) | 0.219 |
III | 10 (90.9) | 8 (66.7) | 0.317 |